Sclerotherapy for lymphangioma in children

Uso de OK-432 em crianças com linfangioma

“…1 Microcystic lymphangioma (capillary or cavernous) exhibited a poorer response OK-432. [1][2][3]7,8,10 Even in the absence of a complete response, there was a significant volume reduction in two of the patients suffering from microcystic lymphangioma (50-60%). This could facilitate surgery in the case it becomes necessary.…”

“…In more recent work, authors have indicated OK-432 even for lesions where there is a risk of airway obstruction, the support of an intensive care team is necessary in this situation. 8,10 The great advantage of OK-432 over other sclerosing agents is, without doubt, the aesthetic results afforded by this drug. None of the patients exhibited any type of scarring after application.…”

“…This being so, there is no increase in difficulty for later surgery. 1,5,8 All of this drug s side effects are reversible. In a sample taking in 30,000 cases treated with OK-432 there were no reported deaths and remission from fever and local inflammation was achieved in a maximum of 14 dias.…”

“…[1][2][3][4][5][6][7][8] The limitations of surgical solutions have awoken interest in other therapeutic methods, such as the administration of sclerosing agents such as bleomycin and hypotonic salt solutions that provoke an inflammation of the vascular endothelium leading to total or partial remission of the lymphangioma. [1][2][3][4][5][6]8 These substances can be diffused, via the walls of the cyst, to adjacent tissues, which can provoke an inflammatory reaction and scar retraction, which may extend beyond the limits of the original lymphangioma, with unsatisfactory aesthetic results and increased difficulties for future surgery. 4 Despite the limitations that make sclerosing agents unsatisfactory for the treatment of lymphangioma, a new agent, OK-432, produced by lyophilization of a culture of low virulence Su strains of group A Streptococcus pyogenes treated with penicillin G potassium, has been used with good results.…”

“…4 Despite the limitations that make sclerosing agents unsatisfactory for the treatment of lymphangioma, a new agent, OK-432, produced by lyophilization of a culture of low virulence Su strains of group A Streptococcus pyogenes treated with penicillin G potassium, has been used with good results. [1][2][3][5][6][7][8][9][10] It has been approved for use by the Japanese Health Ministry for use as a biological response modifier and was initially used in clinical trials for neoplasms of the head and neck. 11 Since 1987, OK-432 has been used for lymphangioma treatment in counties such as Japan.…”